SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
External view of AstraZeneca's production plant in Sweden
Regulatory
AstraZeneca’s Imfinzi Scores Lung Cancer Wins With FDA’s NSCLC Approval, SCLC Priority Review
Imfinzi’s perioperative approval comes after both the FDA’s staffers and a panel of external experts expressed concerns about overtreatment when using the PD-L1 blocker both before and after surgery.
August 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Healthcare worker draws from a vial of an mpox vaccine
Vaccines
Bavarian Nordic Sees Potential Windfall Opportunity Amid Global Mpox Emergency
The company can make 10 million doses available next year, with $600 million to $1 billion in revenue potential into 2025, “albeit perhaps lower on price, discounts and donations,” according to Jefferies analyst Peter Welford.
August 16, 2024
 · 
2 min read
 · 
Tristan Manalac
Photo of a judge's gavel, a balance and a stack of papers
Patents
Delaware Judge Throws Out Pfizer’s $107.5M Tagrisso Patent Win Over AstraZeneca
Just months after a jury ordered payment to Pfizer in the patent infringement case, a Delaware judge has nullified the award and invalidated the patents behind the lawsuit involving AstraZeneca’s blockbuster lung cancer drug.
August 16, 2024
 · 
2 min read
 · 
Tristan Manalac
U.S. Capitol surrounded by money and pill bottles/Taylor Tieden for BioSpace
Policy
IRA-Negotiated Drug Prices as Expected but Savings Not as Great as CMS Says
The Biden administration on Thursday touted discounts of up to 79%, but many of these first 10 drugs are already sold well below list price.
August 15, 2024
 · 
5 min read
 · 
Greg Slabodkin
Illustration of employee being laid off
Layoffs
Evotec Latest in String of August Biopharma Layoff Announcements
Workforce reductions for the first half of August outpace May, June and July’s monthly totals.
August 15, 2024
 · 
2 min read
 · 
Angela Gabriel
Drug Development
Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations
Lori and guests address clinical trial design, which if done without careful consideration of the patient population can exclude patients from clinical trials instead of being inclusive.
August 15, 2024
 · 
1 min read
 · 
Lori Ellis
Gilead's corporate headquarters in Silicon Valley
Approvals
Gilead’s $4.3B Bet on CymaBay Pays Off With FDA Nod for Autoimmune Liver Disease Drug
The regulator’s approval of Livdelzi for primary biliary cholangitis under the accelerated pathway is a boost to Gilead Sciences’ liver disease business. Analysts expect the drug to reach more than $1 billion in sales.
August 15, 2024
 · 
2 min read
 · 
Tristan Manalac
Incyte's logo on its building in Delaware
Approvals
Incyte Wins Second Graft-Versus-Host Disease FDA Approval
Nearly two weeks ahead of its target action date, the regulator on Wednesday has signed off on Incyte and Syndax’s Niktimvo for the third-line treatment of graft-versus-host disease.
August 15, 2024
 · 
2 min read
 · 
Tristan Manalac
Concept art of a gene therapy showing a syringe injecting into a 3D DNA helix
Gene therapy
Bluebird Hit With Slow Uptake of Sickle Cell, Beta-Thalassemia Gene Therapies
Likely to miss its initiation target, bluebird bio has renegotiated the loan deals of its agreement with Hercules Capital, giving it until June 30 next year—at the latest.
August 15, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS